From: IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19
Total (N = 74) | IP-10 | P | |||||
---|---|---|---|---|---|---|---|
Low (N = 34) | High (N = 40) | ||||||
n | Median (IQR) | n | Median (IQR) | n | Median (IQR) | ||
IL-1β, pg/mL | 29 | 5.0 (5.0–5.0) | 11 | 5.0 (5.0–5.0) | 18 | 5.0 (5.0–7.3) | 0.253 |
IL-2R, U/mL | 30 | 1055.5 (464.5–1609.5) | 12 | 784.0 (362.8–1256.3) | 18 | 1311.5 (721.0–1957.0) | 0.099 |
IL-6, pg/mL | 48 | 74.2 (17.0–157.5) | 23 | 26.3 (9.6–95.9) | 25 | 114.8 (54.6–343.1) | 0.001 |
IL-8, pg/mL | 29 | 51.7 (12.5–114.7) | 11 | 19.5 (10.1–51.7) | 18 | 78.8 (22.3–156.0) | 0.018 |
IL-10, pg/mL | 29 | 11.4 (5.0–20.1) | 11 | 5.0 (5.0–9.0) | 18 | 16.8 (8.5–36.4) | 0.001 |
TNFα, pg/mL | 27 | 12.7 (7.5–28.7) | 10 | 8.6 (5.5–10.7) | 17 | 16.2 (8.9–37.1) | 0.021 |
Prothrombin time (PT), s | 71 | 15.9 (14.9–18.2) | 32 | 15.6 (14.7–17.3) | 39 | 16.9 (15.3–19.0) | 0.029 |
Prothrombin activity (PTA), % | 71 | 69.0 (55.0–80.0) | 32 | 71.5 (60.0–80.8) | 39 | 63.0 (51.0–74.0) | 0.025 |
International normalized ratio (INR) | 71 | 1.26 (1.15–1.49) | 32 | 1.24 (1.14–1.41) | 39 | 1.36 (1.20–1.58) | 0.026 |
Fibrinogen (FIB), g/L | 71 | 4.2 (3.1–5.2) | 32 | 4.0 (3.5–4.7) | 39 | 4.6 (2.5–5.7) | 0.675 |
Activated partial thromboplastin time (APTT), s | 71 | 44.5 (39.3–52.6) | 32 | 43.0 (37.5–50.2) | 39 | 46.8 (40.7–57.4) | 0.069 |
Thrombin time (TT), s | 71 | 15.3 (14.5–16.5) | 32 | 15.1 (14.4–15.8) | 39 | 15.8 (14.9–17.7) | 0.016 |
d-Dimer, μg/mL FEU | 71 | 3.85 (1.68–13.46) | 32 | 2.52 (1.32–8.56) | 39 | 5.73 (2.33–18.00) | 0.056 |
Fibrin degradation products (FDP), μg/mL | 30 | 17.2 (6.2–68.6) | 13 | 9.4 (4.0–52.3) | 17 | 17.7 (13.6–130.5) | 0.089 |
Antithrombin (AT), % | 34 | 80.5 (65.5–88.5) | 16 | 83.0 (66.8–92.3) | 18 | 78.5 (62.5–85.8) | 0.48 |